Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)

The report reviews Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Affibody AB

Anacor Pharmaceuticals, Inc.

Apexigen, Inc.

Cell Medica Limited

Handok Inc.

Immune Response BioPharma, Inc.

Novartis AG

Omnitura Therapeutics Inc.

Opsona Therapeutics Limited

Peptinov SAS

R-Pharm

Regeneron Pharmaceuticals Inc

TWi Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Overview 8

Therapeutics Development 9

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Stage of Development 9

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Therapy Area 10

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Indication 11

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Companies 15

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Universities/Institutes 18

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Companies Involved in Therapeutics Development 26

AbbVie Inc 26

Affibody AB 27

Anacor Pharmaceuticals, Inc. 28

Apexigen, Inc. 29

Cell Medica Limited 30

Handok Inc. 31

Immune Response BioPharma, Inc. 32

Novartis AG 33

Omnitura Therapeutics Inc. 34

Opsona Therapeutics Limited 35

Peptinov SAS 36

R-Pharm 37

Regeneron Pharmaceuticals Inc 38

TWi Pharmaceuticals, Inc. 39

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Drug Profiles 40

ABT-981 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

AN-4161 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

APX-002 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

canakinumab - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

diacerein - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

DLX-2323 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

DLX-2681 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

HL-2351 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

IR-1000 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

IR-1002 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

IR-888 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

melittin - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

OMN-54 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

PPV-01 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Recombinant Protein to Inhibit IL-1 Beta for Autoimmune Disorder and Inflammation - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

rilonacept - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

RPH-104 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecule Inflammasome Modulator Programme - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Dormant Projects 67

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Discontinued Products 72

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Featured News & Press Releases 75

Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment 75

Jun 23, 2016: CHMP adopts extension to existing therapeutic indication for Canakinumab 75

Apr 27, 2016: Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes 76

Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 76

Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet 77

Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients 78

Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting 79

Oct 27, 2015: TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes 79

Aug 03, 2015: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia 80

Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan 80

Dec 22, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 81

Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan 81

Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States 81

Jun 26, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States 82

Sep 10, 2013: TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States 82

Appendix 84

Methodology 84

Coverage 84

Secondary Research 84

Primary Research 84

Expert Panel Validation 84

Contact Us 84

Disclaimer 85

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by AbbVie Inc, H2 2016 26

Pipeline by Affibody AB, H2 2016 27

Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 28

Pipeline by Apexigen, Inc., H2 2016 29

Pipeline by Cell Medica Limited, H2 2016 30

Pipeline by Handok Inc., H2 2016 31

Pipeline by Immune Response BioPharma, Inc., H2 2016 32

Pipeline by Novartis AG, H2 2016 33

Pipeline by Omnitura Therapeutics Inc., H2 2016 34

Pipeline by Opsona Therapeutics Limited, H2 2016 35

Pipeline by Peptinov SAS, H2 2016 36

Pipeline by R-Pharm, H2 2016 37

Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 38

Pipeline by TWi Pharmaceuticals, Inc., H2 2016 39

Dormant Projects, H2 2016 67

Dormant Projects (Contd..1), H2 2016 68

Dormant Projects (Contd..2), H2 2016 69

Dormant Projects (Contd..3), H2 2016 70

Dormant Projects (Contd..4), H2 2016 71

Discontinued Products, H2 2016 72

Discontinued Products (Contd..1), H2 2016 73

Discontinued Products (Contd..2), H2 2016 74

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared